Management of Moderate to Severe Plaque Psoriasis (Part I): Clinical Update on Antitumor Necrosis Factor Agents
February 2009 | Volume 8 | Issue 2 | Original Article | 147 | Copyright © 2009
Jeffrey M. Sobell MD, Robert E. Kalb MD, Jeffrey M. Weinberg MD
Psoriasis is an immunologic disorder mediated by T cells and proinﬂammatory cytokines. Novel biologic therapies, targeted at key pathogenic steps, have been developed and provide efﬁcacy without the potential end-organ toxicity induced by traditional therapies. The biologic therapies currently approved for treatment of psoriasis are classiﬁed into 2 categories, as deﬁned by their mechanism of action: inhibition of tumor necrosis factor (TNF) (etanercept, inﬂiximab, adalimumab) and modulation of pathogenic activated T cells (alefacept, efalizumab). This review has been prepared in 2 parts: Part 1 focuses on anti-TNF agents and includes new data that have become available through increased clinical experience and use in eligible patients. Part 2 will present new data on T-cell modulators, new molecules in development, and considerations for optimal therapeutic selection for treatment of patients with psoriasis (Journal of Drugs in Dermatology, March 2009).
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close